ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Letter to the Editor: IOM Study Welcome For “Omic” Research

October 29, 2010

HEW To Pay All Care Cost At 26 Hospices

January 11, 1980

Fermilab Treats 1,000th Patient

August 7, 1981

New ACR Mammography Guidelines Suggest Annual Screening For Women Age 40-50

November 12, 1982

New Law Allows Texans To Self-Refer To M.D. Anderson

December 1, 1995

Medicare: Clinton Budget Revives Proposal To End Physician Drug Markup

February 6, 1998